Goulder, Philip

Phenotypic Analysis of Antigen-Specific T Lymphocytes

Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science

T-cell and B-cell ImmunologyImmunotherapy and Immune Responses

Cited by 3,544

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature

HIV Research and TreatmentT-cell and B-cell Immunology

Cited by 2,680

Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA

Kiepiela, P., Leslie, A. J., Honeyborne, I., Ramduth, D., Thobakgale, C., Chetty, S., Rathnavalu, P., Moore, C., Pfafferott, K. J., Hilton, L., et al. (2004) · Nature

HIV Research and Treatmentvaccines and immunoinformatics approaches

Cited by 842

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Liu, C., Ginn, H. M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R., Zhou, D., Mentzer, A. J., Zhao, Y., et al. (2021) · Cell

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 669

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

Payne, R. P., Longet, S., Austin, J. A., Skelly, D. T., Dejnirattisai, W., Adele, S., Meardon, N., Faustini, S., Al-Taei, S., Moore, S. C., et al. (2021) · Cell

SARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinations

Cited by 322

Vaccine-induced immunity provides more robust heterotypic immunity than natural infection to emerging SARS-CoV-2 variants of concern.

Skelly, D. T., Harding, A. C., Gilbert-Jaramillo, J., Knight, M. L., Longet, S., Brown, A., Adele, S., Adland, E., Brown, H., Team, M. L., et al. (2021) · Nature Communications

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 216

Two doses of SARS-CoV-2 vaccination induce more robust immune responses to emerging SARS-CoV-2 variants of concern than does natural infection.

Skelly, D. T., Harding, A. C., Gilbert-Jaramillo, J., Knight, M. L., Longet, S., Brown, A., Adele, S., Adland, E., Brown, H., Team, M. L., et al. (2021) · Nature Communications

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 216

Non-immunogenicity of overlapping Gag peptides pulsed on autologous cells after vaccination of HIV infected individuals

Kløverpris, H. N., Jackson, A., Handley, A., Hayes, P., Gilmour, J., Riddell, L., Chen, F., Atkins, M., Boffito, M., Walker, B. D., et al. (2013) · PLoS ONE

HIV Research and TreatmentImmunotherapy and Immune Responses

Cited by 2